Observed arrival · 2026-09-01
Medu Laboratories’ Public Peptide Ledger
An independent testing programme publishes purity, potency, heavy-metal, endotoxin, sterility, and identity results for peptides and research compounds.
Field notes
The programme describes a blind procurement workflow followed by a fixed analytical panel: LC-MS identity, HPLC-UV purity, content and potency, ICP-MS heavy metals, LAL endotoxins, and USP <71> sterility. Its public tables currently name vendors across six compounds, with 126 examined for tirzepatide and 153 for retatrutide. The homepage says individual failures remain visible rather than being averaged into a single score. A separate lot-verification route and free sample-test submission are also exposed.
Observed signals
Read the marks
Editorial observations of this landing page, not a rating.
One card from the complete issue